A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community,

I hope everyone has enjoyed their summer and found some time for rest and relaxation.

We are inspired to see the conversation about FAPI’s applications continue to evolve, as reflected by its presence in programs for two scientific meetings this fall.  I, and other members of the SOFIE team, will be attending the annual EANM Congress, on October 19-23 in Hamburg, Germany.  We hope to see many of you there.

SOFIE is proud to be a Silver Sponsor of the ICPO Theranostics Virtual Summit on November 14-15.  As part of the FAP session on Day 2, I will be providing an update on our SOFIE-sponsored clinical trials.  More information on the Summit program and registration is included below.

Here in the US, our Romeoville, IL, site is cleared for production of [18F]-FAPI-74. We now have three sites (in addition to Gilroy, CA, and Totowa, NJ) for manufacturing of GMP grade [18F]-FAPI-74 for clinical research for academics and pharma services, with more sites planned in the coming year.

We want to acknowledge and thank those of you participating in our Global Outreach Program. In accordance with the terms of your MTA with iTheranostics/SOFIE, we will be sending out an annual progress report. Please be on the lookout and complete the short questionnaire. We appreciate this partnership and wish you all the best with your research progress utilizing FAPI.

As always, it’s a pleasure to connect with our FAPI community. Any suggestions you have on how this newsletter can become a better resource for you are welcome.

Sherly Mosessian, Ph.D.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

UPCOMING ICPO THERANOSTICS VIRTUAL SUMMIT

ICPO THERANOTICS Virtual Summit - 5

The 2024 ICPO Theranostics Virtual Summit, “Radiotheranostics: New Era for Alpha Emitters and Radiopharmaceuticals”, is scheduled November 14-15, 2024. Featured in the robust scientific program are sessions on FAP diagnostics and therapy, and a panel on FAP as an imaging biomarker.  SOFIE proudly supports this event with leading academy and industry experts, and further champion the ICPO’s efforts on improving patient outcomes.  Click here to register for this summit.

FAPI-74 CLINICAL DEVELOPMENT UPDATE

FAPI pipeline 2024

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review

The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review

Pharmaceuticals (Basel). 2024 May 31

Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma

Fibroblast Activation Protein-Directed Imaging Outperforms18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

J Nucl Med. 2024 Aug 1

99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction

99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction

J Nucl Cardiol. 2024 Jul 14

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions will be ready for new application reviews in April.

Copyright 2024 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.